Overexpression Of Vascular Endothelial Growth Factor 165 (Vegf(165)) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis

Tingting Chen,Gengyin Zhou,Quan Zhu,Xian Liu,Tuanzhu Ha,J. L. Kelley,R. L. Kao,D. L. Williams,Chuanfu Li
DOI: https://doi.org/10.1179/joc.2010.22.6.402
2010-01-01
Journal of Chemotherapy
Abstract:Doxorubicin (Dox) has been employed in cancer chemotherapy for a few decades. However its clinical application became restricted because of dose-dependent cardiomyopathy. Recent studies suggest that Dox-induced cardiomyocyte apoptosis is a primary cause of cardiac damage. Vascular endothelial growth factor (VEGF) is a major factor for endothelial cell survival and angiogenesis. We have previously shown that VEGF(165) significantly attenuates oxidative stress-induced cardiomyocytes apoptosis. We hypothesized that VEGF(165) will protect the cardiomyocytes from Dox-induced apoptosis. To evaluate our hypothesis, we transfected cardiomyocytes H9c2 with adenovirus expressing VEGF(165) 24 hours before the cells were challenged with Dox at a concentration of 2 mu M. Cardiomyocyte apoptosis was evaluated by Annexin V-FITC staining and by Western blot detection of cleaved caspase-3. The hypothesis was confirmed, and the protective mechanisms involve the inhibition of death receptor-mediated apoptosis and up-regulation of the prosurvival Akt/NF-kappa B/Bcl-2 signaling pathway.
What problem does this paper attempt to address?